Literature DB >> 32148118

Dietary Supplement Use after Cancer Diagnosis in Relation to Total Mortality, Cancer Mortality and Recurrence: A Systematic Review and Meta-Analysis.

Afroditi Kanellopoulou1, Eleni Riza1, Evangelia Samoli1, Vassiliki Benetou1.   

Abstract

To study post-diagnosis dietary supplement use in relation to total mortality, cancer mortality and recurrence among cancer survivors. PubMed and Cochrane Library were searched until April 2019 for observational studies (OS) and randomized clinical trials (RCT). Pooled risk ratios (RR) were calculated using random-effects models. Compared to no supplementation, calcium supplementation was associated with lower total (RR = 0.88, 95% confidence interval (CI): 0.77-1.00, I2=0%, four OS) and cancer mortality (RR = 0.71, 95% CI: 0.53-0.95, I2=0%, three OS) among all cancer survivors, and cancer mortality among colorectal cancer survivors (RR = 0.66, 95% CI: 0.47-0.94, I2=0%, two OS). Vitamin D supplementation was associated with lower total mortality (RR = 0.86, 95% CI: 0.76-0.99, I2=0%, three OS and two RCT). Among breast cancer survivors, supplementation with vitamin C (RR = 0.79, 95% CI: 0.68-0.92, I2=0%, four OS), D (RR = 0.85, 95% CI: 0.72-0.99, I2=0%, two OS), and E (RR = 0.76, 95% CI: 0.64-0.90, I2=0%, three OS) was associated with lower total mortality, while multivitamins (RR = 0.79, 95% CI: 0.64-0.97, I2=0%, two OS), vitamin C (RR = 0.76, 95% CI: 0.64-0.91, I2=0%, two OS), and E (RR = 0.69, 95% CI: 0.55-0.85, I2=0%, two OS) with lower cancer recurrence. Conclusions: Findings are mostly based on OS. More RCTs are needed to justify any recommendation for use.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32148118     DOI: 10.1080/01635581.2020.1734215

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  8 in total

Review 1.  The role of vitamin D in head and neck cancer.

Authors:  Said Izreig; Michael Hajek; Heather A Edwards; Saral Mehra; Clarence Sasaki; Benjamin L Judson; Rahmatullah W Rahmati
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-03

2.  Association Between Pre-diagnostic Dietary Supplements Intake and Ovarian Cancer Survival: Findings From a Prospective Cohort Study in Chinese Women.

Authors:  Jia-Hui Gu; Ting-Ting Gong; Qi-Jun Wu; Fang-Hua Liu; Zhao-Yan Wen; Chang Gao; Yi-Fan Wei; Zhuo Yang
Journal:  Front Nutr       Date:  2021-12-14

3.  Health-Promoting Lifestyle in Colorectal Cancer Survivors: A Qualitative Study on the Experiences and Perspectives of Colorectal Cancer Survivors and Healthcare Providers.

Authors:  Elahe Ramezanzade Tabriz; Monir Ramezani; Abbas Heydari; Seyed Amir Aledavood
Journal:  Asia Pac J Oncol Nurs       Date:  2021-10-04

Review 4.  Zinc Intakes and Health Outcomes: An Umbrella Review.

Authors:  Jin Li; Dehong Cao; Yin Huang; Bo Chen; Zeyu Chen; Ruyi Wang; Qiang Dong; Qiang Wei; Liangren Liu
Journal:  Front Nutr       Date:  2022-02-08

Review 5.  A Narrative Review of the Safety of Anti-COVID-19 Nutraceuticals for Patients with Cancer.

Authors:  Karlen Stade Bader-Larsen; Elisabeth Anne Larson; Maria Dalamaga; Faidon Magkos
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

Review 6.  Post-Diagnosis Vitamin D Supplement Use and Survival among Cancer Patients: A Meta-Analysis.

Authors:  Qiao-Yi Chen; Sohyun Kim; Bohyoon Lee; Gyeongin Jeong; Dong Hoon Lee; NaNa Keum; JoAnn E Manson; Edward L Giovannucci
Journal:  Nutrients       Date:  2022-08-19       Impact factor: 6.706

7.  Serum 25-Hydroxyvitamin D and Subsequent Cancer Incidence and Mortality: A Population-Based Retrospective Cohort Study.

Authors:  Casey R Johnson; Daniel V Dudenkov; Kristin C Mara; Philip R Fischer; Julie A Maxson; Tom D Thacher
Journal:  Mayo Clin Proc       Date:  2021-08       Impact factor: 11.104

8.  Evaluation of Tegaran Formula ZhenHua cytotoxicity against human cancer cell lines.

Authors:  Panagiotis Parsonidis; Ioanna Vlachou; Alexandra Mamagkaki; Ioannis Bouris; Vasiliki Daikopoulou; Ioannis Papasotiriou
Journal:  PLoS One       Date:  2020-10-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.